Delivery Order SPE2DB22D3401-SPE2DB25FT5JR
- Not listed
- The Defense Logistics Agency awarded a $17,574.35 delivery order to AmerisourceBergen Drug Corp for SKYRIZI 150 mg/ml pen vials under a firm fixed price contract type. This competitive award, issued on August 11, 2025, with an ultimate completion date of August 12, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The delivery location is specified as Conshohocken, Pennsylvania, the company's corporate...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,819.88 to AmerisourceBergen Drug Corp for SKYRIZI 150 MG/ML, a specialty pharmaceutical product. Issued on August 11, 2025, with an ultimate completion date of August 12, 2025, this firm fixed-price delivery order represents a competitively awarded, non-set-aside contract. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a $40,663.63 firm fixed price delivery order to AmerisourceBergen Drug Corp for SKYRIZI 150 MG/ML syringes on August 25, 2025, with completion targeted for August 26, 2025. This non-competed delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) vehicle with DLA Troop Support Medical, valued at $999,999,999 and running through December 2026. The product will be delivered to...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of SKYRIZI 150 MG/ML PenML, a pharmaceutical product, with a ceiling value of $26,166.64. This competitively awarded, firm fixed-price delivery order is set to conclude on August 19, 2025, and will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. The contract represents a continuation of AmerisourceBergen's role as a critical...
- The Defense Logistics Agency awarded a delivery order valued at $67,851.86 to AmerisourceBergen Drug Corp for the supply of SKYRIZI 150 mg/ml pen, a pharmaceutical product for federal medical procurement needs. This firm fixed-price delivery order, issued on August 14, 2025, with an ultimate completion date of August 15, 2025, was competitively awarded without set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order valued at $37,510.45 to AmerisourceBergen Drug Corp for the supply of SKYRIZI 150 mg/mL, a pharmaceutical product. This firm fixed price contract, issued on July 21, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999 comprehensive pharmaceutical supply agreement running through December 2026. The contract was competitively awarded...
- The Defense Logistics Agency awarded a $50,801.12 delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of SKYRIZI 150 mg/mL pen/mL, a pharmaceutical product used to treat inflammatory conditions. This is a firm fixed-price contract with no set-aside designation, competitively awarded to the prime contractor. The order is scheduled for completion by July 24, 2025, with performance based in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency awarded a $11,830.00 delivery order to AmerisourceBergen Drug Corp for SKYRIZI 360 mg/2.4 mL on-body 2.4 mL pharmaceutical product. The contract is a firm fixed price delivery order with an ultimate completion date of August 8, 2025, and was awarded on July 18, 2025. This award represents a non-set-aside, competitively awarded contract and constitutes a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of SKYRIZI 150 mg/mL pen medication, valued at $17,239.18. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was made through open competition. The delivery is scheduled for completion by August 25, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency (DLA) on July 23, 2025, for SKYRIZI 150 mg/ml pen medication. This firm fixed-price contract, valued at $35,400.44, represents a non-competitive set-aside delivery order with an ultimate completion date of July 24, 2025. The award leverages AmerisourceBergen's established position within the federal pharmaceutical supply...
- SPE2DB22D3401Indefinite Delivery Contract
- SPE2DB22D3401-SPE2DB25FT5JRDelivery Order
The Defense Logistics Agency awarded a $11,830 delivery order to AmerisourceBergen Drug Corp for SKYRIZI 150 MG/ML, a pharmaceutical product, with performance in Conshohocken, Pennsylvania. This firm fixed price delivery order, awarded on July 30, 2025, represents a non-competitive award executed as a child contract under a larger indefinite delivery vehicle. The award is part of AmerisourceBergen's extensive pharmaceutical supply relationship with the federal government, supporting military and veteran healthcare systems through the DLA's Medical Supply Chain. This delivery order draws from AmerisourceBergen's significant $999,999,999 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical through December 2026, designated as SPE2DX. The prime contract serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains to support military healthcare programs worldwide. The DLA plans to establish Pharmaceutical Prime Vendor Global Program Generation V contracts with multiple regional awards, positioning AmerisourceBergen to continue serving Defense Health Agency, U.S. Coast Guard, and other government healthcare systems through this flexible contracting framework.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.8k | 7/30/25 |